GSM Doesn't Card at the Door: What Every Woman Should Know About Vaginal Tissue Changes at Any Age

The Name Is Misleading — and That's Part of the Problem

When physicians use the term Genitourinary Syndrome of Menopause, or GSM, most patients assume it belongs to a conversation they don't need to have for decades. The word "menopause" functions as a gatekeeper, inadvertently signaling that this condition is irrelevant to younger women. That assumption is both medically inaccurate and quietly harmful.

GSM describes a constellation of symptoms rooted in estrogen deficiency — symptoms that affect vaginal, vulvar, and urinary tissue regardless of whether a woman has reached natural menopause. Breast cancer survivors on aromatase inhibitors, postpartum and breastfeeding women, those using certain hormonal contraceptives, athletes with exercise-induced amenorrhea, and women who have undergone surgical removal of the ovaries can all experience the same tissue changes that are typically associated with the menopausal transition. The common thread is not age. It is estrogen.

Understanding this distinction is the first step toward getting appropriate care — and toward stopping the cycle of suffering in silence that far too many women describe.

What Actually Happens to Vaginal Tissue When Estrogen Drops

Estrogen is not merely a reproductive hormone. It is a tissue-maintenance agent. In the vaginal canal, the vulva, and the lower urinary tract, estrogen receptors are densely concentrated. When circulating estrogen levels fall — for any reason — these tissues begin to lose moisture, elasticity, and thickness.

The vaginal epithelium, which normally maintains a plush, well-lubricated surface, gradually thins. The natural acidity of the vaginal environment shifts, making the tissue more vulnerable to irritation and infection. Collagen production slows. Blood flow to the region decreases. The result is a cascade of physical changes that can manifest as dryness, burning, itching, painful intercourse (medically termed dyspareunia), urinary urgency, and recurrent urinary tract infections.

Because these changes occur gradually, many women normalize them. They assume discomfort during sex is expected, that their bodies have simply changed, or that nothing can be done. Clinicians, meanwhile, may not screen for GSM in younger patients because the diagnostic framework does not prompt them to look.

Who Is Actually at Risk — Beyond the Obvious

The populations most frequently overlooked in GSM conversations include:

Breast cancer survivors and those on anti-estrogen therapies. Aromatase inhibitors and selective estrogen receptor modulators, prescribed to reduce breast cancer recurrence risk, can suppress estrogen to levels lower than those seen in natural menopause. GSM in this group is both more severe and more difficult to treat, given that systemic estrogen therapy is often contraindicated.

Postpartum and breastfeeding women. Prolactin, the hormone that drives milk production, suppresses estrogen. Many new mothers experience significant vaginal dryness and discomfort during intercourse in the months following childbirth — a reality that is often dismissed as simply "part of recovery" rather than addressed as a treatable condition.

Women with hypothalamic amenorrhea. Intense exercise, low body weight, or chronic stress can suppress the hormonal axis that drives estrogen production, leaving younger women with tissue changes more commonly seen in their postmenopausal counterparts.

Women using certain hormonal contraceptives. Some formulations of combined oral contraceptives, particularly those with lower estrogen doses or specific progestin profiles, have been associated with vulvovaginal dryness in a subset of users.

Women who have undergone bilateral oophorectomy. Surgical menopause induced by ovary removal produces an abrupt and significant estrogen drop that can trigger GSM symptoms within weeks.

Why So Many Women Go Undiagnosed

Several structural factors contribute to the persistent underdiagnosis of GSM in younger populations. First, the condition is not routinely screened for during well-woman visits, even when patients present with related symptoms. Second, many women feel embarrassed to raise concerns about vaginal discomfort or painful sex, particularly with a provider they perceive as unlikely to take the complaint seriously.

Research consistently shows that a substantial gap exists between the prevalence of GSM symptoms and the rate at which women seek or receive treatment. A survey published in Menopause found that fewer than one in four women with moderate to severe GSM symptoms had discussed them with a healthcare provider. Among younger women, that number is likely lower still.

The consequence is not merely discomfort. Untreated GSM can significantly affect sexual function, intimate relationships, quality of life, and even urinary health over time. It is not a cosmetic issue. It is a medical one.

A Practical Guide to Treatment Options

The good news is that GSM is one of the more treatable conditions in women's sexual health. The therapeutic landscape spans pharmaceutical interventions, non-hormonal products, and behavioral strategies — meaning there are meaningful options even for women who cannot or prefer not to use estrogen.

Prescription Hormonal Therapies

Localized, low-dose vaginal estrogen is considered the gold standard for GSM treatment in most women. It is available in several forms: creams, suppositories, tablets, and a slow-release vaginal ring. Because the estrogen is delivered directly to vaginal tissue rather than absorbed systemically in significant quantities, these formulations are generally considered safe for many women who cannot use systemic hormone therapy — though women with a history of hormone-sensitive cancers should consult closely with their oncologist.

Ospemifene (brand name Osphena) is an oral selective estrogen receptor modulator approved by the FDA specifically for dyspareunia associated with GSM. It acts on vaginal tissue without behaving as an estrogen in breast tissue, making it an option for some women who are not candidates for vaginal estrogen.

Prasterone (Intrarosa), a vaginal suppository containing DHEA, converts locally to both estrogen and testosterone within vaginal tissue and has demonstrated efficacy for pain during intercourse without meaningful systemic hormone elevation.

Non-Hormonal Options

For women who are not candidates for any hormonal treatment, or who prefer to begin with non-pharmaceutical approaches, several evidence-informed options exist.

Vaginal moisturizers — not to be confused with lubricants — are applied regularly (typically every two to three days) and work to restore and maintain vaginal moisture over time. Products containing hyaluronic acid, polycarbophil, or vitamin E have demonstrated clinical benefit in reducing dryness and discomfort.

Personal lubricants used during sexual activity can meaningfully reduce friction and pain in the short term. Water-based and silicone-based formulations are both well-tolerated; oil-based products are generally not recommended with latex barriers.

Pelvic floor physical therapy, while not a treatment for the tissue changes themselves, can address the muscular guarding and tension that often develop as a secondary response to painful intercourse, improving overall sexual function.

Lifestyle and Supportive Measures

Regular sexual activity — including solo stimulation — supports vaginal health by promoting blood flow to pelvic tissue. This is not merely anecdotal; the physiological mechanism is well-documented. Women who maintain genital blood flow experience less tissue atrophy over time.

Avoiding harsh soaps, scented products, and tight synthetic fabrics in the vulvar region reduces unnecessary irritation to already-sensitive tissue.

Starting the Conversation With Your Provider

If any of the symptoms described here resonate — dryness, burning, pain during intercourse, urinary discomfort — the most important step is raising the issue directly at your next appointment. You do not need to wait until your symptoms become severe, and you do not need to accept discomfort as inevitable.

If your provider dismisses your concerns or does not seem familiar with GSM as a condition affecting younger women, it is entirely appropriate to seek a second opinion from a gynecologist or sexual medicine specialist. The North American Menopause Society (NAMS) maintains a directory of certified menopause practitioners, many of whom are well-versed in GSM across age groups.

Your vaginal health matters at every stage of life. The age on your driver's license does not determine whether you deserve answers — or effective treatment.